XRP6258 is a novel taxane that has been shown to be active in patients with hormone refractory prostate cancer (HRPC) who have failed or progressed after prior therapy with docetaxel (Taxotere) and prednisone, the standard first-line treatment for HRPC. CORT is conducting a study of XRP6258 plus prednisone versus standard mitoxantrone (Novantrone) and prednisone in HRPC patients who have failed prior Taxotere therapy.
The risks of XRP6258 are sensory neuropathy, fatigue, nausea, vomiting, low blood counts, fever, infection, allergic reaction, or hair loss. The risks of standard mitoxantrone therapy are fatigue, hair loss, low blood counts, fever, infection, mouth ulcers, or cardiac dysfunction.
For more information on our research studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: androgen independent prostate cancer, docetaxel, hormone refractory prostate cancer, Prostate Cancer, taxanes, Taxotere, XRP6258
Center for Oncology Research & Treatment--Dallas, TX 
March 9, 2010 at 9:05 pm |
The results of this study were reported at the American Society of Clinical Oncology 2010 Genitourinary Cancer Symposium. This study was the “TROPIC” trial. XRP6258 is now known as cabazitaxel. Results showed that cabazitaxel and prednisone signficantly reduced the risk of death by 30% (harzard ratio HR=0.70, DI: 0.59-0.83; P,0.0001) with a meaningful improvement in median overall survival of 15.1 months in the cabazitaxel plus prednisone group, compared to 12.7 months in the mitoxantrone plus prednisone group.
The TROPIC study was conducted at 146 sites in 26 countries. A total of 755 patients participated. CORT thanks all of the patients who participated in the study, helping to gather this important information.